Clinical Trial

Pharmacological Management of Seizures Post Traumatic Brain Injury

Study acronym: MAST

Not Yet Recruiting Phase 3

Record status

This record was last updated November 3, 2020 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

The overall aim of the MAST trial is to define best practice in the use of anti-epileptic drugs (AEDs) for patients following a traumatic brain injury (TBI). The trial will consist of two parts. The first part aims to answer whether a shorter or a longer course of AEDs is better to prevent further seizures in patients who have started having seizures following TBI (MAST - duration). The second part aims to answer whether a 7-day course of either Phenytoin or Levetiracetam should be used for patients with a serious TBI to prevent seizures from starting (MAST- prophylaxis).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2020-09-28.

Trial Details

NCT Number	NCT04573803
Lead Sponsor	Cambridge University Hospitals NHS Foundation Trust Collaborators: University of Cambridge
Conditions	Traumatic Brain Injury, Post Traumatic Seizures
Enrollment	1,649 participants
Start Date	2021-03-01
Primary Completion	2026-03-01 (estimated)
Study Completion	2028-03-01 (estimated)
Updated on ClinicalTrials.gov	2020-11-03